![](images/graphics/blank.gif)
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
Chia sẻ: ViNaypyidaw2711 ViNaypyidaw2711 | Ngày: | Loại File: PDF | Số trang:17
![](images/blank.gif)
11
lượt xem 0
download
lượt xem 0
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resistance to tamoxifen, and acquired resistance evolves in 40 % of patients who initially respond.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD